Vaccinating against the absent: Risks of the B/Yamagata strain in the live attenuated vaccine
2024

Risks of the B/Yamagata Strain in Influenza Vaccines

publication Evidence: moderate

Author Information

Author(s): Koul Parvaiz A

Primary Institution: Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, India

Hypothesis

Is the B/Yamagata strain of influenza virus still circulating and should it be included in vaccines?

Conclusion

The B/Yamagata strain is no longer justified for inclusion in influenza vaccines due to its drastic decline in circulation.

Supporting Evidence

  • The WHO recommends against including the B/Yamagata strain in future vaccines due to its low circulation.
  • Concerns exist about the potential reintroduction of the B/Yamagata strain through live vaccines.
  • Recent cases have shown that live vaccines can lead to infections in immunocompromised individuals.

Takeaway

The B/Yamagata virus might not be around anymore, so we shouldn't keep vaccinating against it, but there's a chance it could come back.

Limitations

The article discusses the potential for the B/Yamagata strain to re-emerge and the risks associated with live vaccines.

Digital Object Identifier (DOI)

10.2807/1560-7917.ES.2024.29.49.2400766

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication